Travere Therapeutics (TVTX) is up 16.2%, or $5.72 to $41.08.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Cantor Fitzgerald sees Dimerix news as positive for Travere Therapeutics
- Travere Therapeutics rises 13.2%
- Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Anticipated FILSPARI Approval and Strategic Initiatives
- Ligand initiated with a Buy at Citi
- Positive Outlook for Travere Therapeutics: Buy Rating Backed by Strong Clinical Data and Market Expansion Potential